OPM receives ERDF fund totalling €2.1 M for its COMETE program

Dijon (France), January 25 2024 , at 8:00 am CET Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer is pleased to announce that it has receive notification of the allocation of financial support from the European Regional Development Fund (ERDF) under the FEDER SSE+ program for Bourgogne Franche Comté and Massif du Jura 2021 2027 program (Action “PR1 RSO1.1 TA1 Soutenir les projets de recherche collaboratifs dans les doma ines de la stratégie de spécialisation intelligente Supporting collaborative research projects in the fields covered by the smart specialisation strategy ))), aimed at improving research and innovation.